Company: INMB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001213900-25-041072
Chunk: 58

Company: Inmune Bio, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 2
Chunk 58
---
 support its current and future operations, satisfy its obligations and otherwise operate
on an ongoing basis.

We incurred a net loss of
$9.7 million and $11.0 million for the three months ended March 31, 2025 and 2024, respectively. Net cash used in operating activities
was $6,824,000 and $7,476,000 for the three months ended March 31, 2025 and 2024, respectively. Since inception, we have funded our operations
primarily with proceeds from the sales of our common stock. As of March 31, 2025, we had cash and cash equivalents of $19,336,000. We
anticipate that operating losses and net cash used in operating activities will increase over the next few years as we advance our products
under development.

During the period from April 1, 2025 through May 8, 2024, the Company sold 279,966 shares of common stock at an average price of $7.62
for gross proceeds of approximately $2.1 million under the ATM offering.

Our
primary uses of capital are, and we expect will continue to be, third-party clinical and preclinical research and development services,
costs incurred to manufacture our drugs under development, compensation and related expenses, legal, patent and other regulatory expenses
and general overhead costs. We believe our use of CROs provides us with flexibility in managing our spending.

The
Company incurs significant research and development expenses in Australia and the United Kingdom. Fluctuations in the rate of exchange
between the United States dollar and the pound sterling as well as the Australian dollar could adversely affect our financial results,
including our expenses as well as assets and liabilities. We currently do not hedge foreign currencies but will continue to assess whether
that strategy is appropriate. As of March 31, 2025, the cash balance held by our foreign subsidiaries with currencies other than the United
States dollar was approximately $0.1 million.

Our
recurring net losses and negative cash flows from operations, as well as forecast of continued losses and negative cash flows from operations,
raised substantial doubt regarding our ability to continue as a going concern within one year after the issuance of our unaudited condensed
consolidated financial statements for the year ended March 31, 2025. Until we can generate sufficient revenue from the commercialization
of our product candidates, we expect to finance our operations through the public or private sale of